Balyasny Asset Management LLC Zynerba Pharmaceuticals, Inc. Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$2.89 - $7.91 $37,483 - $102,592	-12,970 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.59 - $10.45 $72,502 - $135,536	12,970 New	12,970 $106,000
Q1 2018 May 15, 2018	SELL	$8.49 - $13.46 $1.43 Million - $2.27 Million	-168,500 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$8.69 - $14.59 $520,670 - $874,174	59,916 Added 55.18%	168,500 $2.11 Million
Q3 2017 Nov 14, 2017	BUY	$5.73 - $9.44 $622,186 - $1.03 Million	108,584	108,584 $908,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.